Mutant nucleophosmin 1 peptide-HLA-A*0201 complex (NPM1mut-HLA-A*0201)

The mutant nucleophosmin 1 peptide-HLA-A*0201 complex is a molecular complex formed when peptide fragments derived from the mutated portion of NPM1, commonly seen in acute myeloid leukemia, are presented on the cell surface by the MHC class I molecule HLA-A*0201[6]. This neoantigen is highly immunogenic and exclusive to leukemic cells harboring NPM1 mutations, making it a precise target for immunotherapies that aim to direct cytotoxic T-cells or antibody-based therapies against malignant cells while sparing healthy tissue[6][7]. T-cell and antibody responses against this complex have been demonstrated in AML patients, and it is under investigation as the basis for novel targeted immunotherapies, including peptide vaccines and TCR/CAR-T cell therapies[4][6][7].

Other names

NPM1 mutant-HLA-A2 complexNPM1c-HLA-A*0201 complexNPM1mut/HLA-A2NPM1 mutant peptide/MHC I complex

Recognition by cytotoxic (CD8+) T-cells, leading to targeted lysis of AML cells presenting the mutant peptide[6]. Monoclonal antibodies or CAR T-cells bind to the complex, mediating immune killing of leukemia cells[7]. Therapeutic vaccines induce or enhance T-cell responses against leukemic cells by presenting NPM1 mutant epitopes[6].